

Onconova Therapeutics, Inc.  
 Form 3  
 May 21, 2015

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*

Maniar Manoj  
 (Last) (First) (Middle)

C/O ONCONOVA THERAPEUTICS, INC., 375 PHEASANT RUN

(Street)

NEWTOWN, PA 18940

(City) (State) (Zip)

2. Date of Event Requiring Statement

(Month/Day/Year)  
 04/27/2015

3. Issuer Name and Ticker or Trading Symbol  
 Onconova Therapeutics, Inc. [ONTX]

4. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer  Other  
 (give title below) (specify below)  
 SVP - Product Development

5. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)

2. Amount of Securities Beneficially Owned (Instr. 4)

3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)

4. Nature of Indirect Beneficial Ownership (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and Expiration Date (Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)

4. Conversion or Exercise Price of Derivative Security

5. Ownership Form of Derivative Security: Direct (D)

6. Nature of Indirect Beneficial Ownership (Instr. 5)

Date Exercisable

Expiration Date

Title

Amount or Number of

Edgar Filing: Onconova Therapeutics, Inc. - Form 3

				Shares		or Indirect (I) (Instr. 5)	
Stock Option (right to buy)	08/01/2007	08/01/2017	Common Stock	11,252	\$ 6	D	Â
Stock Option (right to buy)	03/17/2010	03/17/2020	Common Stock	37,509	\$ 5.76	D	Â
Stock Option (right to buy)	03/17/2010	03/17/2020	Common Stock	18,754	\$ 5.76	D	Â
Stock Option (right to buy)	12/10/2010	12/10/2020	Common Stock	7,501	\$ 6.13	D	Â
Stock Option (right to buy)	12/10/2010	12/10/2020	Common Stock	18,754	\$ 6.13	D	Â
Stock Option (right to buy)	12/05/2011	12/05/2021	Common Stock	3,780	\$ 6.13	D	Â
Stock Option (right to buy)	Â <u>(1)</u>	12/18/2022	Common Stock	30,007	\$ 13.28	D	Â
Stock Option (right to buy)	Â <u>(2)</u>	07/25/2023	Common Stock	5,000	\$ 15	D	Â
Stock Option (right to buy)	Â <u>(3)</u>	12/20/2023	Common Stock	40,000	\$ 13.48	D	Â
Stock Option (right to buy)	Â <u>(4)</u>	12/18/2024	Common Stock	60,000	\$ 3.98	D	Â
Stock Option (right to buy)	Â <u>(5)</u>	04/16/2025	Common Stock	40,000	\$ 2.32	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Maniar Manoj C/O ONCONOVA THERAPEUTICS, INC. 375 PHEASANT RUN NEWTOWN, PA 18940	Â	Â	Â SVP - Product Development	Â

## Signatures

/s/ Ajay Bansal, as attorney  
in fact

05/21/2015

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

## Edgar Filing: Onconova Therapeutics, Inc. - Form 3

- (1) This option, representing a right to buy, vests over 4 years, with 25% vesting on December 18, 2013 and 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the issuer.
- (2) This option, representing a right to buy, vests over 4 years, with 25% vesting on July 25, 2014 and 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the issuer.
- (3) This option, representing a right to buy, vests in 48 equal monthly installments over 4 years. The first shares vest one month after the date of grant, which was December 20, 2013.
- (4) This option, representing a right to buy, vests in 48 equal monthly installments over 4 years. The first shares vest one month after the date of grant, which was December 18, 2014.
- (5) This option, representing a right to buy, vests in 48 equal monthly installments over 4 years. The first shares vest one month after the date of grant, which was April 16, 2015.

Â

**Remarks:**

ExhibitÂ 24Â attached.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.